Zoetis Inc. $ZTS Shares Bought by Ieq Capital LLC

Key Points

• Ieq Capital LLC increased its stake in Zoetis Inc. by 23.9%, acquiring a total of 33,918 shares valued at approximately $5.585 million.
• Multiple institutional investors, including Vanguard Group and Polen Capital Management, have adjusted their holdings in Zoetis, with institutional ownership currently at 92.80%.
• ZTS stock reports a moderate buy rating from analysts with a current consensus price target of $202.43, despite recent downgrades by some firms.

Ieq Capital LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 23.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,918 shares of the company's stock after acquiring an additional 6,541 shares during the quarter. Ieq Capital LLC's holdings in Zoetis were worth $5,585,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Zoetis by 87.6% during the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after purchasing an additional 120 shares during the last quarter. Sound Income Strategies LLC grew its position in Zoetis by 141.4% during the 1st quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after purchasing an additional 164 shares during the last quarter. Bfsg LLC grew its position in Zoetis by 614.6% during the 1st quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after purchasing an additional 252 shares during the last quarter. Finally, Garde Capital Inc. purchased a new position in Zoetis during the 1st quarter worth $49,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of NYSE ZTS traded down $3.49 during midday trading on Tuesday, hitting $152.91. The company had a trading volume of 1,467,626 shares, compared to its average volume of 3,062,432. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The business has a 50-day simple moving average of $153.49 and a two-hundred day simple moving average of $157.85. The firm has a market capitalization of $67.77 billion, a price-to-earnings ratio of 26.32, a price-to-earnings-growth ratio of 2.51 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have issued reports on ZTS. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler lifted their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $202.43.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.